Tags

Type your tag names separated by a space and hit enter

[Efficacy and safety of Yimusake Tablets plus dapoxetine hydrochloride in the treatment of premature ejaculation].
Zhonghua Nan Ke Xue. 2016 Sep; 22(9):817-822.ZN

Abstract

OBJECTIVE

To evaluate the effect and safety of Yimusake Tablets combined with dapoxetine hydrochloride and either of them used alone in the treatment of premature ejaculation (PE).

METHODS

We randomly assigned 180 PE patients to oral medication of Yimusake Tablets at 1.5 g per night (group A), dapoxetine hydrochloride at 30 mg at 1－3 hours before anticipated sexual activity (group B), the Yimusake Tablets plus dapoxetine hydrochloride simultaneously (group C), all for 8 weeks. After 4 and 8 weeks of medication, we recorded and compared the changes in the intravaginal ejaculation latency time (IELT), measures of the PE profile (PEP), and adverse events among the three groups of patients.

RESULTS

The treatment was accomplished and complete data obtained from 154 of the patients, 56 in group A, 52 in group B, and 46 in group C. After 4 and 8 weeks of medication, the mean IELT was dramatically prolonged in all the three groups as compared with the baseline (P<0.01), most significantly at 8 weeks in group C (［2.08±0.68］ min), followed by B (［1.76±0.52］ min) and A (［1.47±0.44］ min), with statistically significant differences among the three groups (P<0.01). The PEP measures were remarkably improved in group A at 8 weeks (P<0.05), and both in B and C at 4 and 8 weeks (P<0.05), most significantly at 8 weeks in group C (P<0.05), in which the patients scored 1.96±0.77 in perception of control over ejaculation, 2.62±0.98 in satisfaction with sexual intercourse, 3.04±0.62 in PE-related distress, and 3.57±0.80 in PE-induced difficult relationship with their partners, all markedly improved as compared with groups A and B (P<0.05). Adverse reactions were observed in 2 cases (3.6%) in group A, 6 cases (9.6%) in B, and 5 cases (10.9%) in C. No severe adverse events occurred in any of the patients during the study.

CONCLUSIONS

Combined medication of Yimusake Tablets and dapoxetine hydrochloride, with its advantages of effectiveness and safety, deserves to be recommended for the treatment of PE.

Authors+Show Affiliations

Yan XQ
Department of Urology, The 159th Hospital of the People's Liberation Army, Zhumadian, Henan 463000, China.
Li YF
Department of Urology, Research Institute of Field Surgery, Daping Hospital, The Third Military Medical University, Chongqing 400042, China.
Yang DK
Department of Urology, The 159th Hospital of the People's Liberation Army, Zhumadian, Henan 463000, China.
Jiao X
Department of Urology, The 159th Hospital of the People's Liberation Army, Zhumadian, Henan 463000, China.

MeSH

Administration, OralAdultBenzylaminesCoitusDrug Therapy, CombinationDrugs, Chinese HerbalEjaculationHumansMaleNaphthalenesPersonal SatisfactionPremature EjaculationSexual BehaviorTabletsTime FactorsTreatment Outcome

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

chi

PubMed ID

29071880

Citation

Yan, Xiang-Qian, et al. "[Efficacy and Safety of Yimusake Tablets Plus Dapoxetine Hydrochloride in the Treatment of Premature Ejaculation]." Zhonghua Nan Ke Xue = National Journal of Andrology, vol. 22, no. 9, 2016, pp. 817-822.
Yan XQ, Li YF, Yang DK, et al. [Efficacy and safety of Yimusake Tablets plus dapoxetine hydrochloride in the treatment of premature ejaculation]. Zhonghua Nan Ke Xue. 2016;22(9):817-822.
Yan, X. Q., Li, Y. F., Yang, D. K., & Jiao, X. (2016). [Efficacy and safety of Yimusake Tablets plus dapoxetine hydrochloride in the treatment of premature ejaculation]. Zhonghua Nan Ke Xue = National Journal of Andrology, 22(9), 817-822.
Yan XQ, et al. [Efficacy and Safety of Yimusake Tablets Plus Dapoxetine Hydrochloride in the Treatment of Premature Ejaculation]. Zhonghua Nan Ke Xue. 2016;22(9):817-822. PubMed PMID: 29071880.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Efficacy and safety of Yimusake Tablets plus dapoxetine hydrochloride in the treatment of premature ejaculation]. AU - Yan,Xiang-Qian, AU - Li,Yan-Feng, AU - Yang,Deng-Ke, AU - Jiao,Xiang, PY - 2017/10/27/entrez PY - 2017/10/27/pubmed PY - 2017/12/14/medline KW - Yimusake Tablets KW - dapoxetine hydrochloride KW - intravaginal ejaculation latency time KW - premature ejaculation KW - premature ejaculation profile SP - 817 EP - 822 JF - Zhonghua nan ke xue = National journal of andrology JO - Zhonghua Nan Ke Xue VL - 22 IS - 9 N2 - OBJECTIVE: To evaluate the effect and safety of Yimusake Tablets combined with dapoxetine hydrochloride and either of them used alone in the treatment of premature ejaculation (PE). METHODS: We randomly assigned 180 PE patients to oral medication of Yimusake Tablets at 1.5 g per night (group A), dapoxetine hydrochloride at 30 mg at 1－3 hours before anticipated sexual activity (group B), the Yimusake Tablets plus dapoxetine hydrochloride simultaneously (group C), all for 8 weeks. After 4 and 8 weeks of medication, we recorded and compared the changes in the intravaginal ejaculation latency time (IELT), measures of the PE profile (PEP), and adverse events among the three groups of patients. RESULTS: The treatment was accomplished and complete data obtained from 154 of the patients, 56 in group A, 52 in group B, and 46 in group C. After 4 and 8 weeks of medication, the mean IELT was dramatically prolonged in all the three groups as compared with the baseline (P<0.01), most significantly at 8 weeks in group C (［2.08±0.68］ min), followed by B (［1.76±0.52］ min) and A (［1.47±0.44］ min), with statistically significant differences among the three groups (P<0.01). The PEP measures were remarkably improved in group A at 8 weeks (P<0.05), and both in B and C at 4 and 8 weeks (P<0.05), most significantly at 8 weeks in group C (P<0.05), in which the patients scored 1.96±0.77 in perception of control over ejaculation, 2.62±0.98 in satisfaction with sexual intercourse, 3.04±0.62 in PE-related distress, and 3.57±0.80 in PE-induced difficult relationship with their partners, all markedly improved as compared with groups A and B (P<0.05). Adverse reactions were observed in 2 cases (3.6%) in group A, 6 cases (9.6%) in B, and 5 cases (10.9%) in C. No severe adverse events occurred in any of the patients during the study. CONCLUSIONS: Combined medication of Yimusake Tablets and dapoxetine hydrochloride, with its advantages of effectiveness and safety, deserves to be recommended for the treatment of PE. SN - 1009-3591 UR - https://www.unboundmedicine.com/medline/citation/29071880/[Efficacy_and_safety_of_Yimusake_Tablets_plus_dapoxetine_hydrochloride_in_the_treatment_of_premature_ejaculation]_ DB - PRIME DP - Unbound Medicine ER -